This webinar will provide an overview and FDA guidance to firms that are either going through or preparing to go through clinical trial training and working with clinical investigators. In Spring 2011, FDA released its draft guidance to replace its current guidance on disclosure of financial interests held by clinical investigator training. The draft guidance reflects the changing landscape both within and outside FDA regarding transparency of financial interests. Consistent with increased public attention to physician-industry ties and connections, the tone of the guidance suggests or infers that clinical trial sponsors should expect a more rigorous review by FDA.

Date : 16th February 2016 to 16th February 2016

Place : United States, New hyde park

Website :https://complianceglobal.us/product/700281/DavidRDills/financial-disclosure-by-clinical-investigators/1

Contact Person:Compliance Global Inc

Description:

This webinar will provide an overview and FDA guidance to firms that are either going through or preparing to go through clinical trial training and working with clinical investigators. In Spring 2011, FDA released its draft guidance to replace its current guidance on disclosure of financial interests held by clinical investigator training. The draft guidance reflects the changing landscape both within and outside FDA regarding transparency of financial interests. Consistent with increased public attention to physician-industry ties and connections, the tone of the guidance suggests or infers that clinical trial sponsors should expect a more rigorous review by FDA.

This webinar will provide an overview and FDA guidance to firms that are either going through or preparing to go through clinical trial training and working with clinical investigators. In Spring 2011, FDA released its draft guidance to replace its current guidance on disclosure of financial interests held by clinical investigator training. The draft guidance reflects the changing landscape both within and outside FDA regarding transparency of financial interests. Consistent with increased public attention to physician-industry ties and connections, the tone of the guidance suggests or infers that clinical trial sponsors should expect a more rigorous review by FDA. will be held in New hyde park,United States on date 2016-02-16

---

Deadline for abstracts/proposals : 16th February 2016

Keynote Speakers : David R. Dills, an independent Regulatory & Compliance Consultant with more than 22 years of hands-on experience and a proven track record within the life sciences and FDA regulated industry, has an extensive regulatory background with Class I/II/III and IVD devices and managing and handling activities within the global regulatory landscape. He manages quality, regulatory and compliance projects with multiple competing priorities having a direct impact on site operations and commercial op

Conference Highlights :Overview This webinar will provide an overview and FDA guidance to firms that are either going through or preparing to go through clinical trial training and working with clinical investigators. In Spring 2011, FDA released its draft guidance to replace its current guidance on disclosure of financial interests held by clinical investigator training. The draft guidance reflects the changing landscape both within and outside FDA regarding transparency of financial interests. Consistent with

Venue :Compliance Global Inc., 2754 80th Avenue, New Hyde Park, NY 11040, United States

Check the event website for more details.